Table 1.
Characteristics and treatment details of patients with esophageal carcinoma included in this study (N = 20)
| Characteristics | Data |
|---|---|
| Sex, n (%) | |
| Male/ Female | 15 (75) / 5 (25) |
| Age, years, median (range) | 70 (54–85) |
| Tumor location, n (%) | |
| Cervical/ Upper/ Middle/ Lower thoracic | 2 (10) / 8 (40) / 6 (30) / 4 (20) |
| SUVmax | |
| mean | 12.1 |
| median, range | 10.7 (3.6–31.6) |
| T classification, n (%) | |
| T2/ T3/ T4 | 4 (20) / 15 (75) / 1 (5) |
| N classification, n (%) | |
| N0 / N1/ N2 | 5 (25) / 10 (50) / 5 (25) |
| Stage, n (%) | |
| II/ III/ IV | 6 (30) / 8 (40) / 6 (30) |
| Concurrent chemotherapy | |
| Yes/ No | 9 (45) / 11 (55) |
| Dose of proton radiotherapy | |
| median, range | 50 Gy (44–56) / 25 fractions (22–28) |
| Dose of carbon ion radiotherapy | |
| median, range | 21 Gy (15–23.1) / 7 fractions (5–7) |
Doses are presented as the RBE (relative biological effectiveness)-weighted dose
Abbreviations: SUVmax, the maximum standard uptake value